ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2776

Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis

Nicolò Pipitone1, Francesco Muratore2, Ione Tamagnini3, Alberto Cavazza4, Luca Cimino5, Luigi Boiardi2, Giovanna Restuccia6, Martina Bonacini7, Stefania Croci7 and Carlo Salvarani8, 1Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, 2Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, 3Pathology Unit, Department of Oncology, Arsicpedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 4Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 5Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 6Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, 7Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, 8Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biopsies, giant cell arteritis and temporal arteritis, IL-6

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate if interleukin-6 (IL-6) expression in the temporal artery biopsy (TAB) specimens may differentiate patients with giant cell arteritis (GCA) from those without.

Methods: 63 consecutive formalin-fixed, paraffin-embedded (FFPE) TABs performed between 2009 and 2012 from 32 patients with transmural biopsy-proven GCA, 8 patients with biopsy-negative GCA and 23 controls were retrieved. Demographic, clinical, and laboratory data at presentation and at each follow-up visit were collected. A pathologist reviewed all TABs. Immunohistochemistry was performed on 4μm FFPE tissue sections with a 1:400 dilution of rabbit polyclonal anti-human IL-6 antibody (NOVUS Biologicals Littleton, Co.) for 60’ at 37°. Slides of TAB specimens were independently assessed by five readers. IL-6 expression was graded as 0 (absent), 1 (mild), 2 (moderate) and 3 (marked). Inter-reader differences were resolved by consensus. Anti-IL6 staining was considered positive if staining was grade 2 or 3, since grade 1 was faint, sometimes difficult to differentiate from background, and showed the least degree of agreement between Readers.

Results: TAB specimens from patients with biopsy-proven GCA, biopsy-negative GCA and controls were positive for anti-IL-6 staining in 59%, 13% and 48% of cases, respectively, the difference between biopsy-proven and biopsy-negative GCA patients being significant (p = 0.04). In non-inflamed TABs, IL-6 was mainly expressed by mesenchymal cells in media and intima layers, while in inflamed TABs IL-6 was mainly expressed by mononuclear inflammatory infiltrating cells. IL-6 grade 2-3 expression was observed in all 6 patients with visual loss compared to 25 (43.9%) of 57 patients without (p = 0.011). Blindness was recorded in 2 patients with biopsy-proven GCA and 4 controls (all with a final diagnosis of non-arteritic ischemic optic neuropathy). No associations were found between IL-6 expression and demographic characteristics, GCA signs/symptoms, laboratory and histopathological TAB findings. However, there was a statistical trend (p = 0.055) of increased frequency of the halo sign at temporal artery CDS in patients with IL-6 expression grade 2-3 compared to those with IL-6 expression grade 0-1. No significant differences for the expression of IL-6 were observed between patients with and without PMR (5/8 – 62.5% – versus 6/15 – 40% -, p = 0.400) and between patients with isolated PMR and those with TAB positive GCA (62.5% vs 59%, p = 1.000).

Conclusion: Our study provides evidence that IL-6 expression does not increase the sensitivity of TAB in patients with morphologically uninflamed arteries. A search for further markers that may increase the sensitivity of TAB is warranted.


Disclosure: N. Pipitone, None; F. Muratore, None; I. Tamagnini, None; A. Cavazza, None; L. Cimino, None; L. Boiardi, None; G. Restuccia, None; M. Bonacini, None; S. Croci, None; C. Salvarani, None.

To cite this abstract in AMA style:

Pipitone N, Muratore F, Tamagnini I, Cavazza A, Cimino L, Boiardi L, Restuccia G, Bonacini M, Croci S, Salvarani C. Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/interleukin-6-expression-in-inflamed-and-non-inflamed-temporal-arteries-from-patients-with-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-6-expression-in-inflamed-and-non-inflamed-temporal-arteries-from-patients-with-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology